FLNA
$2.00
Post-MarketAs of Mar 17, 8:00 PM UTC
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.00
Potential Upside
5%
Whystock Fair Value$2.10
Price
UndervaluedFair ValueOvervalued
Fundamentals
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's dise...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$96.62M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.84
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-82.66%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.18
Recent News
No recent news found.